دورية أكاديمية
أعرض في EDS

Tau expression correlated with breast cancer sensitivity to taxanes-based neoadjuvant chemotherapy.

التفاصيل البيبلوغرافية
العنوان: Tau expression correlated with breast cancer sensitivity to taxanes-based neoadjuvant chemotherapy.
المؤلفون: Wang K; Department of Breast Cancer, Cancer Center, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, 510080, China., Deng QT, Liao N, Zhang GC, Liu YH, Xu FP, Zu J, Li XR, Wu YL
المصدر: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine [Tumour Biol] 2013 Feb; Vol. 34 (1), pp. 33-8. Date of Electronic Publication: 2012 Sep 14.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: IOS Press Country of Publication: Netherlands NLM ID: 8409922 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1423-0380 (Electronic) Linking ISSN: 10104283 NLM ISO Abbreviation: Tumour Biol Subsets: MEDLINE
أسماء مطبوعة: Publication: 2021- : Amsterdam, The Netherlands : IOS Press
Original Publication: Tokyo, Japan : Saikon Pub. Co., c1984-
مواضيع طبية MeSH: Neoadjuvant Therapy*, Antineoplastic Agents/*therapeutic use , Breast Neoplasms/*drug therapy , Paclitaxel/*therapeutic use , tau Proteins/*metabolism, Biomarkers, Tumor/metabolism ; Breast Neoplasms/metabolism ; Chemotherapy, Adjuvant ; Female ; Humans ; Middle Aged ; Receptor, ErbB-2/metabolism ; Receptors, Estrogen/metabolism ; Receptors, Progesterone/metabolism ; Treatment Outcome ; tau Proteins/immunology
مستخلص: The purpose of this study was to investigate the correlation between tau expression in primary breast cancer and sensitivity to taxanes during neoadjuvant chemotherapy in patients with breast cancer. We used immunohistochemistry to examine tau expression in breast cancer biopsies from 113 primary breast cancer patients and evaluated the correlation between tau expression and taxane sensitivity. Twenty-eight (24.78 %, 28/113) patients were positive for tau expression. After taxanes-based neoadjuvant chemotherapy, 40 patients achieved pathological complete response (pCR) (35.4 %). Among the 40 patients with pCR, five (12.5 %) were positive for tau expression. In univariate analysis, estrogen receptor (ER), progesterone receptor, human epidermal growth factor receptor 2 (HER2), and tau were found to be significantly predictive of a pCR (P = 0.001, 0.030, 0.002, and 0.025, respectively). Tau, ER, and HER2 status were significant for pCR on multivariate analysis (P = 0.025, 0.005, and 0.043, respectively). Tau expression was positively related to ER (P = 0.007) and progestin receptor (P = 0.008). In conclusion, tau protein expression correlated with breast cancer sensitivity to taxanes-based neoadjuvant chemotherapy; patients negative for tau expression were more likely to achieve pCR.
References: Cell Cycle. 2005 Sep;4(9):1149-52. (PMID: 16103753)
Breast Cancer Res Treat. 2009 Jul;116(1):131-43. (PMID: 18668363)
Breast Cancer Res. 2010;12(3):R43. (PMID: 20579400)
Surg Oncol. 2008 Dec;17(4):301-11. (PMID: 18467090)
Clin Cancer Res. 2010 Aug 1;16(15):3988-97. (PMID: 20576719)
Breast Cancer Res Treat. 2008 Mar;108(2):183-90. (PMID: 17468948)
Clin Cancer Res. 2007 Jul 15;13(14):4078-82. (PMID: 17634532)
J Clin Oncol. 2005 Jun 1;23(16):3686-96. (PMID: 15897552)
J Clin Oncol. 2007 Jul 1;25(19):2650-5. (PMID: 17602071)
Cancer Treat Rev. 2012 Nov;38(7):890-903. (PMID: 22465195)
N Engl J Med. 2007 Oct 11;357(15):1496-506. (PMID: 17928597)
J Clin Oncol. 2006 Sep 10;24(26):4236-44. (PMID: 16896004)
Biochemistry. 1992 Nov 3;31(43):10626-33. (PMID: 1420178)
Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8315-20. (PMID: 15914550)
J Thorac Dis. 2010 Sep;2(3):160-70. (PMID: 22263038)
EMBO J. 2003 Jan 2;22(1):70-7. (PMID: 12505985)
Clin Cancer Res. 2007 Apr 1;13(7):2061-7. (PMID: 17404087)
J Clin Oncol. 2003 Mar 15;21(6):976-83. (PMID: 12637460)
Breast Cancer Res. 2011 Nov 02;13(5):R85. (PMID: 21888627)
J Clin Oncol. 1999 Feb;17(2):460-9. (PMID: 10080586)
Br J Cancer. 2004 Dec 13;91(12):2012-7. (PMID: 15558072)
J Clin Oncol. 2009 Sep 10;27(26):4287-92. (PMID: 19667268)
Breast. 2007 Feb;16(1):86-93. (PMID: 17010609)
Clin Transl Oncol. 2008 Oct;10(10):646-53. (PMID: 18940745)
المشرفين على المادة: 0 (Antineoplastic Agents)
0 (Biomarkers, Tumor)
0 (MAPT protein, human)
0 (Receptors, Estrogen)
0 (Receptors, Progesterone)
0 (tau Proteins)
EC 2.7.10.1 (ERBB2 protein, human)
EC 2.7.10.1 (Receptor, ErbB-2)
P88XT4IS4D (Paclitaxel)
تواريخ الأحداث: Date Created: 20120915 Date Completed: 20130328 Latest Revision: 20211021
رمز التحديث: 20231215
DOI: 10.1007/s13277-012-0507-z
PMID: 22976542
قاعدة البيانات: MEDLINE
الوصف
تدمد:1423-0380
DOI:10.1007/s13277-012-0507-z